Quantcast

AxoGen, Inc. to Participate in Educational Symposium at American Association of Tissue Banks 2013 Spring Meeting

April 3, 2013

AxoGen´s Avance® Nerve Graft technology to be discussed in educational session on peripheral nerve allograft

Alachua, FL (PRWEB) April 03, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it will be participating in the American Association of Tissue Banks (AATB) 2013 Spring Meeting, April 6-9 in Tucson, Arizona.

AATB´s 2013 Spring Meeting is focused on providing education on innovation in tissue banking technology. As the first and only commercially available processed nerve allograft, AxoGen´s Avance® Nerve Graft will be featured in a session on Peripheral Nerve Allografts on Sunday afternoon, April 7. In the session, healthcare professionals and other attendees will learn about advances in the processing of donated peripheral nerve tissue and clinical experience with nerve allograft transplantation. In addition, attendees will have the opportunity to meet and hear the recovery story of patient Edward Bonfiglio who received an AxoGen nerve allograft after being injured while serving as a Navy Corpsman in Afghanistan in 2009.

“As the only company processing donated peripheral nerve tissue, AxoGen is proud to partner with the AATB to provide education on innovation in tissue processing technologies,” said Karen Zaderej, CEO of AxoGen. “Our proprietary Avance® Process for cleansing nerve tissue has allowed us to offer healthcare professionals and their patients the option of peripheral nerve repair using an allograft technology. Since our commercial introduction, thousands of patients have received an Avance® Nerve Graft for the repair of a nerve injury.”

The American Association of Tissue Banks (AATB) is the only national tissue banking organization in the United States and has set the standard for tissue banking globally. The organization is dedicated to improving and saving lives by promoting the safety, quality and availability of donated human tissue and reports that its accredited members, including AxoGen, distribute in excess of two million allografts for more than one million tissue transplants performed annually in the U.S. with demand rising steadily.

About AxoGen, Inc.

AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company´s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen´s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen´s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10596476.htm


Source: prweb



comments powered by Disqus